The nuclear localization of mTOR has been also observed in rhabdomyosarcomas (Rh30 and Rh41), human fibroblasts (IMR90), multiple myeloma cells and colon carcinoma cells (HCT8) and was frequently implicated in resistance to anticancer therapies, including tyrosine kinase inhibitors, radiation and cytotoxic drugs. Here, MTOR is linked to plasma cell myeloma.